Guinea-Bissau Police Seize Vaccines From Controversial Newborn Hepatitis B Trial

Police in Guinea-Bissau have seized hepatitis B vaccines from a research centre linked to a suspended US-funded trial involving 14,000 newborns. The World Health Organization criticised the study as unethical because it proposed withholding a proven vaccine from some babies. The investigation aims to establish the circumstances surrounding the vaccines, but police stressed that the seizure does not prove they are unsafe. The case has renewed concerns about research ethics and protecting newborns in a country with high hepatitis B infection rates.

POLICE INVESTIGATE VACCINES LINKED TO CONTROVERSIAL STUDY

Police in Guinea-Bissau have seized a batch of hepatitis B vaccines from a research facility linked to a controversial immunisation trial involving newborn babies. The study, which received funding from the United States, has been suspended pending further technical review after the World Health Organization (WHO) raised serious ethical concerns.
The vaccines were confiscated on Monday at the Bandim Health Project, a research centre led by Danish scientists involved in the proposed study. Guinea-Bissau’s judicial police said the seizure was part of an ongoing investigation to establish the circumstances surrounding the specific batch of vaccines.
Authorities stressed that the seizure alone did not prove that the vaccines were defective or that their quality, safety or effectiveness had been compromised. Investigators are seeking to clarify the facts before reaching any conclusions.

WHY THE NEWBORN VACCINE TRIAL CAUSED CONTROVERSY

The proposed study was designed to involve approximately 14,000 newborn babies in Guinea-Bissau, a country in West Africa where hepatitis B remains a significant public health concern.
The research plan would have randomly determined which newborns received the hepatitis B vaccine shortly after birth and which did not receive the birth dose as part of the study. The approach triggered criticism because the vaccine is already widely used and has an established record of preventing infection.
The WHO suspended the study pending further technical review in February and described the proposed approach as unethical. The organisation raised concerns that withholding a proven vaccine from some newborns could expose them to an avoidable risk of infection.
The central issue is whether a research project should deliberately withhold an established preventive measure from some infants when the disease poses a serious threat to public health.

WHY THE HEPATITIS B BIRTH DOSE IS IMPORTANT

Hepatitis B is a viral infection that attacks the liver. It can spread through infected blood and bodily fluids, including from an infected mother to her baby during childbirth.
An infection acquired at birth can become chronic, potentially leading to serious complications such as liver cirrhosis and liver cancer later in life.
The WHO says the hepatitis B vaccine is effective in preventing approximately 70 to 95 percent of mother to child transmission. Giving the vaccine soon after birth is therefore an important part of protecting infants, particularly in countries where hepatitis B is common.
Guinea-Bissau faces a substantial burden from the disease. WHO estimates cited in the report indicate that more than 12 percent of adults in the country have chronic hepatitis B, while approximately two percent of children under five are infected.
These figures highlight the importance of prevention and the concerns surrounding a trial that could leave some newborns without the protection offered by the birth dose.

US FUNDING AND QUESTIONS ABOUT THE RESEARCH

The United States Centers for Disease Control and Prevention awarded a grant of $1.6 million to support the proposed research in Guinea-Bissau.
The Danish researchers associated with the project have previously conducted studies examining possible harmful effects of vaccines. Some aspects of their research methods have attracted scrutiny from members of the scientific community.
However, the current seizure does not establish that the vaccines were unsafe or that the researchers committed wrongdoing. The police have said their investigation is intended to determine the circumstances surrounding the seized batch.
The distinction is important because questions about the ethics of a study, the conduct of researchers and the quality of the vaccines themselves are separate matters that require evidence.

WHY THE WHO OPPOSES WITHHOLDING THE VACCINE

The WHO has emphasised that the hepatitis B vaccine has a strong safety record built on decades of use.
From a public health perspective, withholding an established vaccine from newborns in a country with high infection rates could create preventable risks. Babies infected early in life are particularly vulnerable to developing long term infection, which may cause serious liver disease.
The controversy also raises wider questions about informed consent, the protection of vulnerable participants and the responsibility of researchers conducting studies in low income countries.
Newborns cannot make medical decisions for themselves, so research involving them requires especially careful ethical safeguards. Researchers must demonstrate that a study is scientifically justified and that the risks to participants are appropriately managed.

WHAT THE INVESTIGATION COULD MEAN FOR CHILDREN

Guinea-Bissau’s judicial police said the seizure was intended to safeguard the public interest and protect children's health. The investigation will examine the circumstances surrounding the vaccines, but authorities have not concluded that the batch is unsafe.
The suspended trial also faces the challenge of addressing the ethical and technical concerns raised by the WHO before any decision about proceeding can be made.
For families, the case highlights the importance of reliable vaccination programmes and transparent medical research. For health authorities, it reinforces the need to ensure that research involving infants meets established scientific and ethical standards.
Until investigators and relevant health authorities provide further findings, the seizure should not be interpreted as proof that the vaccines are dangerous. The immediate concern remains ensuring that newborns are protected against hepatitis B while the questions surrounding the proposed trial are properly examined.